Offices of Howard G. Smith announces that it is investigating
potential claims on behalf of investors of InspireMD, Inc. ("InspireMD"
or the "Company") (NYSE MKT:NSPR). The investigation concerns possible
violations of federal securities laws, and focuses on the Company's
operations and financial prospects.
InspireMD is a medical device company focused on the development and
commercialization of proprietary MGuard stent platform technology. The
Company's MGuard stent is an embolic protection device based on a
protective sleeve, which is constructed out of an ultra-thin polymer
msh and wrapped around the stent. The investigation is related to
InspireMD's April 30, 2014, announcement that Company has initiated a
Voluntary Field Action (VFA) following recent reports of MGuard Prime
EPS stent dislodgements. According to the Company, these reports "have
primarily occurred during the preparation of the MGuard Prime EPS, upon
removal of the protective sleeve or during withdrawal of the MGuard
Prime EPS into the guide catheter."
The Company further announced that, as a result of the VFA, the Company
has temporarily suspended enrollment in its MASTER II FDA trial, pending
a review by the U.S. Food and Drug Administration of the modifications
to the MGuard Prime EPS, and anticipates the agency's review is likely
to delay enrollment in the trial for approximately three to six months.
If you purchased InspireMD securities prior to April 30, 2014, if you
have information or would like to learn more about these claims, or if
you have any questions concerning this announcement or your rights or
interests with respect to these matters, please contact Howard G. Smith,
Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite
112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll
Free at (888) 638-4847, or by email to email@example.com,
or visit our website at www.howardsmithlaw.com.
[ Back To NFVZone's Homepage ]